NHS Ruxolitinib Supply Framework Agreement

This is a national framework agreement for the supply of Ruxolitinib to NHS organizations across England. The framework runs from 1 April 2028 to 31 March 2029, with the option to extend for up to an additional 24 months at NHS England's discretion. Ruxolitinib is a JAK inhibitor medication used to treat certain blood and skin conditions. This framework is managed by NHS Medicines Value & Access within Medicines Procurement and Supply Chain (Reference: CM/TNS/26/5755). Eligible suppliers should have established capabilities in pharmaceutical distribution and regulatory compliance. The framework aims to ensure reliable, cost-effective access to Ruxolitinib across the NHS while maintaining supply chain efficiency and quality standards.